ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).
View Top Employees from ERYTECH PharmaWebsite | http://www.erytech.com |
Ticker | ERYP |
Revenue | $6 million |
Funding | $23.1 million |
Employees | 95 (95 on RocketReach) |
Founded | 2004 |
Address | 60 Ave Rockefeller, Lyon, Auvergne-Rhone-Alpes 69008, FR |
Phone | +33 4 78 74 44 38 |
Fax | +33 4 78 75 56 29 |
Technologies |
JavaScript,
HTML,
PHP
+27 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Drug Manufacturing & Research, Biopharma, Drug Discovery, Pharmaceuticals, Healthcare, Health Care, Science and Engineering, Medical |
Web Rank | 4 Million |
Keywords | Erytech, Erytech Pharma, Erytech Pharma Lyon, Erytech Js, Andre Baruchel Bio |
Competitors | Embera NeuroTherapeutics, G1 Therapeutics, Inc., InteRNA Technologies BV, MIS.CARBONART, OxThera |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 62 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 6215 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 621 Companies, NAICS Code 541711 Companies, NAICS Code 62151 Companies |
Looking for a particular ERYTECH Pharma employee's phone or email?
The ERYTECH Pharma annual revenue was $6 million in 2023.
Iman El-Hariry is the Chief Medical Officer of ERYTECH Pharma.
95 people are employed at ERYTECH Pharma.
ERYTECH Pharma is based in Lyon, Auvergne-Rhone-Alpes.
The NAICS codes for ERYTECH Pharma are [62, 541, 54171, 6215, 54, 5417, 621, 541711, 62151].
The SIC codes for ERYTECH Pharma are [28, 283].